Current NIAID Biodefense Research Funding Opportunities
SARS-CoV added to NIAID Category C Priority Pathogens list as of August 30, 2004.
|
| Title |
Relevant Dates |
Focus |
Contact Person |
| Basic Research: pathogen biology, host response, microbial genomic sequencing, and proteomics. |
Immune Function and Biodefense in Children, Elderly, and Immunocompromised Populations
(RFP-NIH-NIAID-DAIT-BAA-05-011) |
January 20, 2005
|
To improve the immune response of immunocompromised individuals to vaccines and immunotherapies that defend against NIAID Category A, B, or C priority pathogens.
|
Suzanne L. Dawkins |
Immune Modeling BAA
(RFP-05-10) |
November 23, 2004
|
To establish Immune Modeling Centers of highly interactive, multi-disciplinary teams to develop innovative mathematical models of immunity to vaccines/therapeutics or infection, with a focus on NIAID Category A, B and C Priority Pathogens.
|
Robert Singman |
Biodefense and Emerging Infections Disease Research Opportunities
(PA-04-119) |
Standard receipt dates |
Basic and applied research on NIAID Category A, B and C Priority Pathogens, their toxic products, and the body's immune defenses against them. |
Sam Perdue
|
Development of Assays for High Throughput Drug Screening
(PA-04-068) |
Standard receipt dates
|
Encourage the use of high throughput small molecule screening for use in both research and drug discovery programs by funding the development of innovative assays that may be adapted for automated screening.
|
Michael G. Kurilla |
NIH Small Research Grant Program (R03)
(PA-03-108) |
Standard receipt dates |
Small research projects; funding for up to 2 years, Not specific to bioterrorism, but bioterrorism-related research is responsive |
Sam Perdue
Alison Deckhut
|
Biodefense SBIR Program
(PAS-02-149) |
Standard receipt dates |
NIAID priority organisms and products for biodefense research |
Barbara Mulach |
Hyperaccelerated Award/Mechanisms in Immunomodulation Trials
(RFA-AI-02-003) |
MONTHLY on the 9th of each month. |
Uses patient samples for the evaluation of immunologic and other relevant parameters to facilitate the study and definition of immunological mechanisms underlying the intervention, the mechanisms of disease pathogenesis, surrogate/biomarkers, markers of disease activity and therapeutic effect, and mechanisms of human immunologic function. |
Kristy Kraemer |
| |
| Title |
Relevant Dates |
Focus |
Contact Person |
| Target Identification: potential vaccines, diagnostics, and immunotherapy targets. |
Disabling Innate Immune Evasion: New Attenuated Vaccines
RFA-AI-04-023 |
Letter of Intent Due: October 26, 2004
Applications due: November 23, 2004 |
The purpose of this RFA is to solicit research projects focused on new approaches for vaccine development. This RFA program is focused on the NIAID Category A, B, and C pathogens, which are listed at http://www.niaid.nih.gov/biodefense/bandc_priority.htm. |
Francesca Macchiarini |
Biodefense SBIR Program
(PAS-02-149) |
Standard receipt dates |
NIAID priority organisms and products for biodefense research |
Barbara Mulach |
Hyperaccelerated Award/Mechanisms in Immunomodulation Trials
(RFA-AI-02-003) |
MONTHLY on the 9th of each month. |
Uses patient samples for the evaluation of immunologic and other relevant parameters to facilitate the study and definition of immunological mechanisms underlying the intervention, the mechanisms of disease pathogenesis, surrogate/biomarkers, markers of disease activity and therapeutic effect, and mechanisms of human immunologic function.
|
Kristy Kraemer |
| Title |
Relevant Dates |
Focus |
Contact Person |
| Preclinical Development: product refinement testing. |
|
Neutralizing Monoclonal Antibodies for Type A Botulinum Toxins
(NIH-NIAID-DMID-PR04-01) |
November 5, 2004 |
To develop and manufacture cGMP bulk drug substance for up to three human or human compatible mAbs with potency demonstrated in a standardized mouse protection bioassay for botulinum neurotoxins A1 and A2. |
Liem T. Nguyen
|
Recombinant Type E Botulinum Neurotoxin Vaccine
(NIH-NIAID-DMID-PR04-02)
Amendment #1 |
November 5, 2004 |
To manufacture cGMP bulk drug substance, approximately 50 grams, of a recombinant type E botulinum neurotoxin vaccine with demonstrated potency in a standardized mouse protection bioassay. The vaccine should be suitable for evaluation as a stand alone vaccine or in combination with other recombinant vaccines for types A and B botulinum neurotoxins. |
Liem T. Nguyen
|
|
SBIR Advanced Technology – NIAID (SBIR-AT-NIAID)
(PA-04-127) |
Standard Receipt Dates |
The goal of this PA is to invite SBIR advanced technology projects that require a longer award period and greater award amount than those routinely allowed under the SBIR program, including:
-Development of vaccines, biologics, drugs and prevention strategies for infectious and immunologic diseases, allergy, and transplantation;
-Development of vaccine, biologic and drug delivery systems;
- Development of assays and therapeutic monitoring systems for clinical and vaccine trials and for improved diagnosis of infectious, allergic, and immunologic diseases. |
Scientific/research issues:
Gregory Milman
Financial/grants management matters:
Pamela Fleming
|
Biodefense SBIR Program
(PAS-02-149) |
Standard receipt dates |
NIAID priority organisms and products for biodefense research |
Barbara Mulach |
|
Tularemia Vaccine Development Team
RFP-NIH-NIAID-DMID-05-22 |
Proposals Due: December 1, 2004 |
The goal of this RFP is to award a contract to support the coordinated development of research tools to identify and evaluate new candidates for a safe, effective, general use tularemia vaccine. The NIAID recognizes that the accomplishment of this goal will require a range of research and development capabilities that may not be readily available in a single institutional entity. Therefore, the contract to be awarded in response to this RFP will support the formation of a collaborative team of diverse researchers, laboratories and other organizations to integrate the necessary expertise, and research and development capabilities into a unified, product-oriented project. |
Elizabeth Osinski |
Challenge Grants: Biodefense Product Development
(RFA-AI-04-029) |
Letter of Intent due: December 17, 2004
Applications due: January 18, 2005 |
This program will support further development of previously identified products against NIAID Category A, B, and C high priority pathogens including vaccines, adjuvants, therapeutics, and diagnostics. To be responsive to this program for the development of biodefense products, the applicant must have already demonstrated proof-of-principle for a candidate vaccine, therapeutic, adjuvant, or diagnostic method for biodefense. Phases of further development eligible for support include, but are not limited to: early validation; pre- clinical stages; scale-up; production; and fulfilling regulatory requirements. |
|
| |
| Title |
Relevant Dates |
Focus |
Contact Person |
| Clinical Evaluation: biodefense therapies, vaccines, and diagnostics |
| |
| Title |
Relevant Dates |
Focus |
Contact Person |
| Research Resources: biodefense research capacity and infrastructure |
| Extramural Research Facilities Improvement Program (PAR-04-122) |
Application due: September 14, 2004; December 15, 2004 |
In collaboration NIAID, NCRR encourages applications for major alteration and renovation (A&R) projects that support the NIAID biodefense and emerging infectious diseases research agenda. Activities that may be supported include major alteration and renovation of existing biosafety level-3 (BSL-3) laboratory/vivarium space, and the upgrade of BSL-2 laboratory/vivarium space to BSL-3 space in existing buildings. |
Willie D. McCullough
|
| Regional Biocontainment Laboratories (RBL) Construction Program (RFA-AI-04-032) |
Letter of Intent due: November 29, 2004
Application due: December 29, 2004 |
NIAID invites applications for Construction Cooperative Agreement (UC6) funds to support the construction of new Regional Biocontainment Laboratories (RBLs) to be used for biomedical research and research training. Funds will be provided to program, design, construct, and commission comprehensive state-of-the-art laboratories that will support research on the NIAID Category A, B and C priority pathogens and emerging infectious diseases. |
Design/construction:
Nancy Boyd
Scientific/research:
Alicia Dombroski
Peer review issues:
John Bogdan
Financial/grants management:
Lesia Norwood
|
Training and Career Development Opportunities - BioD and Emerging Infectious Diseases
(NOT-AI-03-046) |
Standard receipt dates |
Training and career development awards
Click here for more info |
Milt Hernandez |